REG - Sampo PLC - Publication of Supplement to Prospectus <Origin Href="QuoteRef">SAMAS.HE</Origin>

Sampo OyjAnnouncement

10/02/2016 17:10

RNS Number : 7126O
Sampo PLC
10 February 2016
Sampo plc
10 February 2016
Publication of Supplement to Prospectus
The following Supplement has been approved by the UK Listing Authority:
Supplement dated 10 February 2016 to Prospectus dated 26 March 2015 relating to the EUR 3,000,000,000 Euro Medium Term Note Programme of Sampo plc.
The following documents (the "Documents") have been filed with the UK Listing Authority and are available for viewing:
Supplement dated 10 February 2016
Unaudited results for 2015 for the twelve month period ended 31 December 2015
The Documents must be read in conjunction with the Prospectus dated 26 March 2015 and any other supplements thereto. The Prospectus constitutes a base prospectus for the purposes of Article 5.4 of Directive 2003/71/EC as amended. Full information on Sampo plc is only available on the basis of the Prospectus.
To view the full documents, please paste the following URL into the address bar of your browser.
Supplement dated 10 February 2016
http://www.rns-pdf.londonstockexchange.com/rns/7126O_-2016-2-10.pdf

Unaudited results for 2015 for the twelve month period ended 31 December 2015
http://www.rns-pdf.londonstockexchange.com/rns/7126O_1-2016-2-10.pdf

A copy of the above document has been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/nsm
For further information, please contact
Jarmo Salonen
Head of Investor Relations and Group Communications
Tel: +358 10 516 0030
Sampo plc
Registered Office
Fabianinkatu 27
FI-00100 Helsinki
Finland
DISCLAIMER - INTENDED ADDRESSEES
Please note that the information contained in the Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Prospectus is not addressed. Prior to relying on the information contained in the Prospectus you must ascertain from the Prospectus whether or not you are part of the intended addressees of the information contained therein.
In particular, the Prospectus does not constitute an offer of securities for sale in the United States. This is not for distribution in the United States. The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state of the United States of America and are subject to U.S. tax law requirements. Subject to certain exceptions, the securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons or to persons within the United States of America, as such terms are defined in Regulation S under the Securities Act. There will be no public offering of the securities in the United States.
Your right to access this service is conditional upon complying with the above requirement.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
PDIGGUWUPUPQGMU